Patents by Inventor Shi-Hui Liu

Shi-Hui Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10835593
    Abstract: Disclosed is a Bacillus anthracis protective antigen (PA) comprising a PA amino acid sequence, wherein one or more of amino acid residues I207, I210, E654, I656, R659, M662, Y681, and L687, as defined by reference to SEQ ID NO: 1, are, independently, substituted, with the proviso that amino acid residue I207 is not substituted with alanine and amino acid residue I210 is not substituted with alanine. Related compositions, nucleic acids, recombinant expression vectors, host cells, populations of cells, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: November 17, 2020
    Assignee: The United States of America as represented by the Secretary Department of Health and Human Services
    Inventors: Shi-Hui Liu, Stephen H. Leppla, Thomas H. Bugge, Alexander N. Wein, Diane E. Peters, Jie Liu, Kuang-Hua Chen
  • Publication number: 20180250376
    Abstract: Disclosed is a Bacillus anthracis protective antigen (PA) comprising a PA amino acid sequence, wherein one or more of amino acid residues I207, I210, E654, I656, R659, M662, Y681, and L687, as defined by reference to SEQ ID NO: 1, are, independently, substituted, with the proviso that amino acid residue I207 is not substituted with alanine and amino acid residue I210 is not substituted with alanine. Related compositions, nucleic acids, recombinant expression vectors, host cells, populations of cells, methods of treating or preventing cancer in a mammal, and methods of inhibiting the growth of a target cell are also disclosed.
    Type: Application
    Filed: August 25, 2016
    Publication date: September 6, 2018
    Applicant: The United States of America as represented by the Secretary Department of Health and Human Services
    Inventors: Shi-Hui Liu, Stephen H. Leppla, Thomas H. Bugge, Alexander N. Wein, Diane E. Peters, Jie Liu, Kuang-Hua Chen
  • Patent number: 9403872
    Abstract: The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: August 2, 2016
    Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH
    Inventors: Stephen H. Leppla, Shi-Hui Liu, Sarah Netzel-Arnett, Henning Birkedal-Hansen, Thomas Bugge
  • Publication number: 20140378654
    Abstract: The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site.
    Type: Application
    Filed: June 24, 2014
    Publication date: December 25, 2014
    Inventors: Stephen H. LEPPLA, Shi-Hui LIU, Sarah NETZEL-ARNETT, Henning BIRKEDAL-HANSEN, Thomas BUGGE
  • Patent number: 8791074
    Abstract: The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: July 29, 2014
    Assignee: The United States of America as Represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen Leppla, Shi-Hui Liu, Sarah Netzel-Arnett, Henning Birkedal-Hansen, Thomas Bugge
  • Patent number: 8388933
    Abstract: The present invention provides compositions comprising modified bacterial toxins and methods for using the modified bacterial toxins for targeting particular cell populations and for treating diseases.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: March 5, 2013
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services
    Inventors: Stephen H. Leppla, Shi-Hui Liu, Thomas H. Bugge
  • Publication number: 20110280908
    Abstract: The present invention provides compositions comprising modified bacterial toxins and methods for using the modified bacterial toxins for targeting particular cell populations and for treating diseases.
    Type: Application
    Filed: April 15, 2011
    Publication date: November 17, 2011
    Applicants: Services, National Institutes of Health, Office of Technology Transfer
    Inventors: Stephen H. Leppla, Shi-Hui Liu, Thomas H. Bugge
  • Patent number: 7947289
    Abstract: The present invention provides compositions comprising modified bacterial toxins and methods for using the modified bacterial toxins for targeting particular cell populations and for treating diseases.
    Type: Grant
    Filed: February 9, 2005
    Date of Patent: May 24, 2011
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Stephen H. Leppla, Shi-Hui Liu, Thomas H. Bugge
  • Publication number: 20090142794
    Abstract: The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site.
    Type: Application
    Filed: October 20, 2008
    Publication date: June 4, 2009
    Applicants: of Health and Human Services
    Inventors: Stephen H. Leppla, Shi-Hui Liu, Sarah Netzel-Arnett, Henning Birkedal-Hansen, Thomas Bugge
  • Patent number: 7468352
    Abstract: The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site.
    Type: Grant
    Filed: September 22, 2000
    Date of Patent: December 23, 2008
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Stephen H. Leppla, Shi-Hui Liu, Sarah Netzel-Arnett, Henning Birkedal-Hansen, Thomas Bugge
  • Publication number: 20080166375
    Abstract: The present invention provides compositions and methods for inhibiting abnormal cell growth. In particular, the invention provides nucleic acids encoding Diphtheria toxin fusion proteins comprising residues 1-388 of Diphtheria toxin, wherein the native furin cleavage site has been substituted for a matrix metalloproteinase or plasminogen activator cleavage site, and a heterologous polypeptide and the polypeptides encoded by such nucleic acids. In addition, the invention provides methods of treating cancer by administering such polypeptides.
    Type: Application
    Filed: May 6, 2004
    Publication date: July 10, 2008
    Applicant: The Government of the United States of America, as rep. by the Secretary of Health and Human Service
    Inventors: Stephen H. Leppla, Jennifer Avallone, Thomas Bugge, Shi-Hui Liu, Manuel Osorio
  • Publication number: 20050255083
    Abstract: The present invention provides compositions comprising modified bacterial toxins and methods for using the modified bacterial toxins for targeting particular cell populations and for treating diseases.
    Type: Application
    Filed: February 9, 2005
    Publication date: November 17, 2005
    Applicants: Services, National Institutes of Health, Office of Technology Transfer
    Inventors: Stephen Leppla, Shi-Hui Liu, Thomas Bugge
  • Publication number: 20050123476
    Abstract: This invention pertains to methods for imaging the activity of extracellular proteases in cells using the anthrax binary toxin-system to target cells expressing extracellular proteases with mutant anthrax toxin protective antigens (?PrAg) that bind to receptors on the cells and are cleaved by a specific extracellular protease expressed by the cells, and ligands that specifically bind to the cleaved ?PrAg and are linked to a moiety that is detectable by an imaging procedure. The ?PrAg proteins used in the methods comprise a protease cleavage site that is cleaved by a specific extracellular protease and is in place of the furin cleavage site of the native PrAg. The methods are useful for diagnosing and treating diseases and undesirable physiological conditions correlated with the activity of extracellular proteases, and for optimizing the therapeutic efficacy of drugs used to treat such diseases and conditions.
    Type: Application
    Filed: September 5, 2002
    Publication date: June 9, 2005
    Applicant: The Government of the United States as represented by the Secretary of the Department of Health and
    Inventors: Thomas Bugge, Stephen Leppla, Shi-Hui Liu, David Mitola